Immuron Limited (IMRN): Price and Financial Metrics


Immuron Limited (IMRN): $1.85

-0.10 (-5.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IMRN Stock Summary

  • IMMURON LTD's market capitalization of $11,088,084 is ahead of just 4.63% of US-listed equities.
  • For IMRN, its debt to operating expenses ratio is greater than that reported by only 0.44% of US equities we're observing.
  • With a year-over-year growth in debt of -100%, IMMURON LTD's debt growth rate surpasses only 0% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to IMMURON LTD are MTLS, CMCM, CLRO, BKYI, and PHAR.
  • IMRN's SEC filings can be seen here. And to visit IMMURON LTD's official web site, go to www.immuron.com.au.

IMRN Stock Price Chart Interactive Chart >

Price chart for IMRN

IMRN Price/Volume Stats

Current price $1.85 52-week high $3.44
Prev. close $1.95 52-week low $1.39
Day low $1.85 Volume 400
Day high $1.85 Avg. volume 13,268
50-day MA $2.02 Dividend yield N/A
200-day MA $2.22 Market Cap 10.54M

Immuron Limited (IMRN) Company Bio


Immuron Limited focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company was founded in 1994 and is based in Australia.


IMRN Latest News Stream


Event/Time News Detail
Loading, please wait...

IMRN Latest Social Stream


Loading social stream, please wait...

View Full IMRN Social Stream

Latest IMRN News From Around the Web

Below are the latest news stories about IMMURON LTD that investors may wish to consider to help them evaluate IMRN as an investment opportunity.

Immuron First Half 2023 Earnings: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Immuron ( ASX:IMC ) First Half 2023 Results Key Financial Results Net loss: AU$1.98m (loss widened by 9.2% from 1H...

Yahoo | March 3, 2023

Immuron CEO, Steven Lydeamore to host an investor webinar

MELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited. Tuesday, 28 February 2023 at 11:00am Australian Eastern Standard Time (AEDT). To register in advance for this webinar,

Yahoo | February 15, 2023

Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

MELBOURNE, Australia, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, today announces that a response letter has been submitted to the US Food and Drug Administration (FDA). Immuron has previously reported feedback was received from the FDA following a review of the Investigation

Yahoo | January 25, 2023

US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone

Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study157 participants successfully randomized into the Clinical StudyPlans in place to enrol in 1302 healthy volunteers in total Infectious diarrhea is the most common illness reported by travelers & military personnel MELBOURNE, Australia, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially

Yahoo | January 18, 2023

Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease

MELBOURNE, Australia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that has been granted a European Patent for compositions and methods for the treatment and/or prophylaxis of Clostridioides difficile associated disease. Notification of the decision to g

Yahoo | January 17, 2023

Read More 'IMRN' Stories Here

IMRN Price Returns

1-mo -6.09%
3-mo -3.14%
6-mo -16.67%
1-year -44.11%
3-year N/A
5-year N/A
YTD -11.06%
2022 -16.80%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Continue Researching IMRN

Want to see what other sources are saying about Immuron Ltd's financials and stock price? Try the links below:

Immuron Ltd (IMRN) Stock Price | Nasdaq
Immuron Ltd (IMRN) Stock Quote, History and News - Yahoo Finance
Immuron Ltd (IMRN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7693 seconds.